Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoantigen Vaccine and Retifanlimab in MMR-p CRC and PDAC
NCT04799431Phase 1Withdrawn
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- May 2023
- Primary completion
- May 2023
- Modality
- Peptides, Vaccines & Immunotherapeutics
01
Overview
Phase 1, open-label, single-arm trial of NeoVax in colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoints: Percentage of patients who receive at least one dose of personalized neoantigen vaccine at 9 months and Number of participants experiencing study drug-related toxicities at 2 years. Planned start May 2023; status: withdrawn.
02
Drugs
NeoVax
03
Conditions
colorectal cancer (CRC)pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04799431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04799431.